Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year.
Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally.
That’s …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in…
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Endpoints 100 1H 2026 CEO survey: optimism rebounds on hot M&A and IPOs; 64% see MFN delaying ex-US filings as execs demand a…
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
